loading page

Fenebrutinib and BTK inhibition: unveiling a new target for the treatment of chronic spontaneous urticaria
  • Sergio Sánchez Fernández,
  • Carvallo A,
  • Morales-Palacios MP
Sergio Sánchez Fernández
Clinica Universidad de Navarra

Corresponding Author:[email protected]

Author Profile
Carvallo A
Clinica Universidad de Navarra
Author Profile
Morales-Palacios MP
Clinica Universidad de Navarra
Author Profile


Fenebrutinib is an orally administered, selective and reversible BTK inhibitor. Metz et al recently published a double-blind, placebo-controlled, phase 2 trial where fenebrutinib (50mg daily, 150mg daily or 200mg twice-daily) or placebo were randomly administered to 93 adults with CSU refractory to up-dosed H 1-antihistamines during 8 weeks. Fenebrutinib was more effective than placebo in reducing weekly Urticaria Activity Score (UAS7) after 8 weeks, achieving rates of well-controlled disease (UAS7≤6) of up to 57% (with a 200mg twice-daily dose).
13 Oct 2022Submitted to Allergy
14 Oct 2022Submission Checks Completed
14 Oct 2022Assigned to Editor
14 Oct 2022Review(s) Completed, Editorial Evaluation Pending
17 Oct 2022Reviewer(s) Assigned
31 Oct 2022Editorial Decision: Revise Minor
07 Nov 20221st Revision Received
07 Nov 2022Review(s) Completed, Editorial Evaluation Pending
07 Nov 2022Submission Checks Completed
07 Nov 2022Assigned to Editor
09 Nov 2022Reviewer(s) Assigned
22 Nov 2022Editorial Decision: Accept